Compounds > flurbiprofen
Page last updated: 2024-10-27

flurbiprofen and Disease Models, Animal

flurbiprofen has been researched along with Disease Models, Animal in 75 studies

Flurbiprofen: An anti-inflammatory analgesic and antipyretic of the phenylalkynoic acid series. It has been shown to reduce bone resorption in periodontal disease by inhibiting CARBONIC ANHYDRASE.
flurbiprofen : A monocarboxylic acid that is a 2-fluoro-[1,1'-biphenyl-4-yl] moiety linked to C-2 of propionic acid. A non-steroidal anti-inflammatory, analgesic and antipyretic, it is used as a pre-operative anti-miotic as well as orally for arthritis or dental pain.

Disease Models, Animal: Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.

Research Excerpts

ExcerptRelevanceReference
"The modulatory mechanism of flurbiprofen axetil (FPA) by which it relieves cerebral ischemia/reperfusion (I/R) injury (CIRI) is still obscure."8.12Flurbiprofen axetil protects against cerebral ischemia/reperfusion injury via regulating miR-30c-5p and SOX9. ( Nie, Y; Wang, L; Xiong, W; Yang, B, 2022)
"We evaluated the effect of the co-administration of fluoxetine (5 mg/kg) and flurbiprofen (5 mg/kg) or fluoxetine (5 mg/kg) and celecoxib (5 mg/kg) in the chronic escape deficit (CED) model of depression after 7 days of treatment."7.88Neither all anti-inflammatory drugs nor all doses are effective in accelerating the antidepressant-like effect of fluoxetine in an animal model of depression. ( Alboni, S; Benatti, C; Brunello, N; Capone, G; Tascedda, F, 2018)
"Our results suggest that R-flurbiprofen improves the endogenous mechanisms to regain stability after axonal injury and to fend off chronic neuropathic pain by modulating the endocannabinoid system and thus constitutes an attractive, novel therapeutic agent in the treatment of chronic, intractable pain."7.76R-flurbiprofen reduces neuropathic pain in rodents by restoring endogenous cannabinoids. ( Bechmann, I; Bishay, P; Costigan, M; Dehghani, F; Geisslinger, G; Häussler, A; Koch, M; Kuner, R; Marian, C; Metzner, J; Myrczek, T; Schmidt, H; Tegeder, I; Wijnvoord, N; Ziebell, S, 2010)
"Topical instillation of combinations of doxycycline with either flurbiprofen or LMWH can effectively inhibit corneal neovascularization made by chemical cauterization of the cornea in rats."7.73The effect of combinations of flurbiprofen, low molecular weight heparin, and doxycycline on the inhibition of corneal neovascularization. ( Aydin, E; Kazi, AA; Kivilcim, M; Peyman, GA; Riazi-Esfahani, M; Sanders, DR, 2006)
"The potential antinociceptive effects of the S(+)- and R(-)-enantiomers of flurbiprofen (SFB and RFB, respectively) were investigated when given intravenously to rats using the pain-induced functional impairment model in the rat (PIFIR), an animal model of arthritic pain."7.70Analysis of antinociceptive effects of flurbiprofen enantiomers in a rat model of arthritic pain. ( Cabré, F; Díaz, MI; Domínguez, AM; García, ML; Hernández, GP; López-Muñoz, FJ; Mauleón, D; Ventura, R, 2000)
"We investigated the antinociceptive properties of dexketoprofen trometamol [S(+)-ketoprofen tromethamine salt; SKP], a new analgesic, antiinflammatory drug, using the pain-induced functional impairment model in the rat (PIFIR), an animal model of arthritic pain."7.70Antinociceptive effects of S(+)-ketoprofen and other analgesic drugs in a rat model of pain induced by uric acid. ( Cabré, F; Díaz, I; Fernández-Guasti, A; López-Muñoz, FJ; Mauleón, D; Tost, D; Ventura, R, 1998)
"Inflammation which is activated during cerebral ischemia/reperfusion (I/R) is an important mechanism leading to brain injury."5.48Flurbiprofen axetil attenuates cerebral ischemia/reperfusion injury by reducing inflammation in a rat model of transient global cerebral ischemia/reperfusion. ( Guo, P; Hong, J; Jin, Z; Ke, J; Li, X; Tai, LW; Tang, C; Wang, Y; Wu, H; Yang, X; Yao, W, 2018)
"Caffeine is able to increase the effect of rac-Flur in the arthritic gout-type pain in rats."5.43Antinociceptive Effect of Racemic Flurbiprofen and Caffeine Co-Administration in an Arthritic Gout-Type Pain in Rats. ( Espinosa-Juárez, JV; Jaramillo-Morales, OA; Liévano-Reyes, R; López-Muñoz, FJ; Pérez-Méndez, HI; Solís-Oba, A, 2016)
"Main parameter was thrombus weight."5.32Interactions between aspirin and COX-2 inhibitors or NSAIDs in a rat thrombosis model. ( Bégaud, B; Boisseau, M; Moore, N; Umar, A; Upur, H; Yusup, A, 2004)
"The onset of ocular hypertension occurred within 15 min."5.28Argon laser-induced ocular hypertension: animal model of ocular inflammation. ( Gherezghiher, T; Koss, MC, 1989)
"The modulatory mechanism of flurbiprofen axetil (FPA) by which it relieves cerebral ischemia/reperfusion (I/R) injury (CIRI) is still obscure."4.12Flurbiprofen axetil protects against cerebral ischemia/reperfusion injury via regulating miR-30c-5p and SOX9. ( Nie, Y; Wang, L; Xiong, W; Yang, B, 2022)
"We evaluated the effect of the co-administration of fluoxetine (5 mg/kg) and flurbiprofen (5 mg/kg) or fluoxetine (5 mg/kg) and celecoxib (5 mg/kg) in the chronic escape deficit (CED) model of depression after 7 days of treatment."3.88Neither all anti-inflammatory drugs nor all doses are effective in accelerating the antidepressant-like effect of fluoxetine in an animal model of depression. ( Alboni, S; Benatti, C; Brunello, N; Capone, G; Tascedda, F, 2018)
"Our results suggest that R-flurbiprofen improves the endogenous mechanisms to regain stability after axonal injury and to fend off chronic neuropathic pain by modulating the endocannabinoid system and thus constitutes an attractive, novel therapeutic agent in the treatment of chronic, intractable pain."3.76R-flurbiprofen reduces neuropathic pain in rodents by restoring endogenous cannabinoids. ( Bechmann, I; Bishay, P; Costigan, M; Dehghani, F; Geisslinger, G; Häussler, A; Koch, M; Kuner, R; Marian, C; Metzner, J; Myrczek, T; Schmidt, H; Tegeder, I; Wijnvoord, N; Ziebell, S, 2010)
"Current evidence suggests a role of neuroinflammation in the pathogenesis of Parkinson's disease (PD) and in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) model of basal ganglia injury."3.76Combining nitric oxide release with anti-inflammatory activity preserves nigrostriatal dopaminergic innervation and prevents motor impairment in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease. ( Caniglia, S; Impagnatiello, F; L'Episcopo, F; Marchetti, B; Morale, MC; Serra, PA; Testa, N; Tirolo, C, 2010)
"The means of percent area of corneal neovascularization in triamcinolone, doxycycline, flurbiprofen, LMWH, and control groups were 13."3.73Prevention of corneal neovascularization: evaluation of various commercially available compounds in an experimental rat model. ( Aydin, E; Kazi, AA; Kivilcim, M; Peyman, GA; Riazi-Esfahani, M; Sanders, DR, 2006)
"Topical instillation of combinations of doxycycline with either flurbiprofen or LMWH can effectively inhibit corneal neovascularization made by chemical cauterization of the cornea in rats."3.73The effect of combinations of flurbiprofen, low molecular weight heparin, and doxycycline on the inhibition of corneal neovascularization. ( Aydin, E; Kazi, AA; Kivilcim, M; Peyman, GA; Riazi-Esfahani, M; Sanders, DR, 2006)
" We investigated changes in the expression of adenosine type-2B (A2B) receptors and a related intracellular second messenger during chronic brain inflammation and following treatment with the non-steroidal anti-inflammatory drug flurbiprofen and its nitric oxide (NO)-donating derivative, HCT1026."3.72The influence of brain inflammation upon neuronal adenosine A2B receptors. ( Hauss-Wegrzyniak, B; McGann, K; Rosi, S; Wenk, GL, 2003)
"Urethane anaesthesia strongly reduced the peripheral edema (31+/-5 and 96+/-8% reduction of carrageenan-enhanced paw and ankle diameters, respectively; P<0."3.71Urethane anaesthesia could partly mask antinociceptive effects of non-steroidal anti-inflammatory drugs: a spinal c-Fos protein study. ( Besson, JM; Buritova, J, 2001)
"The potential antinociceptive effects of the S(+)- and R(-)-enantiomers of flurbiprofen (SFB and RFB, respectively) were investigated when given intravenously to rats using the pain-induced functional impairment model in the rat (PIFIR), an animal model of arthritic pain."3.70Analysis of antinociceptive effects of flurbiprofen enantiomers in a rat model of arthritic pain. ( Cabré, F; Díaz, MI; Domínguez, AM; García, ML; Hernández, GP; López-Muñoz, FJ; Mauleón, D; Ventura, R, 2000)
"We investigated the antinociceptive properties of dexketoprofen trometamol [S(+)-ketoprofen tromethamine salt; SKP], a new analgesic, antiinflammatory drug, using the pain-induced functional impairment model in the rat (PIFIR), an animal model of arthritic pain."3.70Antinociceptive effects of S(+)-ketoprofen and other analgesic drugs in a rat model of pain induced by uric acid. ( Cabré, F; Díaz, I; Fernández-Guasti, A; López-Muñoz, FJ; Mauleón, D; Tost, D; Ventura, R, 1998)
"Male Lewis rats (n = 78) were randomly assigned to one of 10 groups, comprising controls, adjuvant arthritis (AA), and adjuvant arthritis with various combinations of 2 chemically modified, non-antimicrobial tetracycline derivatives (CMT3 or CMT8) with either of 2 nonsteroidal antiinflammatory agents (flurbiprofen or tenidap)."3.69Administration of systemic matrix metalloproteinase inhibitors maintains bone mechanical integrity in adjuvant arthritis. ( Golub, LM; Greenwald, RA; Leng, W; Moak, SA; Wohl, GR; Zernicke, RF, 1997)
" We have tested the efficacy of topically given S(+)-ibuprofen in a rabbit model of uveitis secondary to the intravitreal injection of human recombinant interleukin 1-alpha."3.68The effects of topical S(+)-ibuprofen on interleukin-1 induced ocular inflammation in a rabbit model. ( Boney, RS; Goldenberg, MM; Rosenbaum, JT; Tilden, ME, 1990)
"The anti-inflammatory effects of flurbiprofen and a number of other antirheumatic agents were studied in the rat using a model of inflammation, which involved the subcutaneous implantation of polyurethane cubes impregnated with an irritant."3.65The effect of anti-inflammatory and antirheumatic drugs on inflammation in the rat. ( Currey, HL; Vernon-Roberts, B; Woodland, J, 1977)
" Epidemiological studies have shown that long-term use of nonsteroidal anti-inflammatory drugs (NSAIDs) reduces the risk of developing AD and delays its onset."2.43Novel therapeutic opportunities for Alzheimer's disease: focus on nonsteroidal anti-inflammatory drugs. ( Praticò, D; Townsend, KP, 2005)
"Flurbiprofen (FP) is one of the most potent nonsteroidal anti-inflammatory drugs with very low bioavailability of approximately 12% following transdermal administration, compared to that after oral administration."1.56Development of galangal essential oil-based microemulsion gel for transdermal delivery of flurbiprofen: simultaneous permeability evaluation of flurbiprofen and 1,8-cineole. ( Chen, J; Dong, J; Dong, YF; Feng, H; Gu, W; Wu, FY; Yang, BQ; Zhu, XM, 2020)
" CDDP-induced nephrotoxicity (CIN) is one of the most severe adverse events associated with the use of CDDP."1.56Comparison of the nephroprotective effects of non-steroidal anti-inflammatory drugs on cisplatin-induced nephrotoxicity in vitro and in vivo. ( Furugen, A; Iseki, K; Kobayashi, M; Narumi, K; Okamoto, K; Saito, Y, 2020)
"Inflammation which is activated during cerebral ischemia/reperfusion (I/R) is an important mechanism leading to brain injury."1.48Flurbiprofen axetil attenuates cerebral ischemia/reperfusion injury by reducing inflammation in a rat model of transient global cerebral ischemia/reperfusion. ( Guo, P; Hong, J; Jin, Z; Ke, J; Li, X; Tai, LW; Tang, C; Wang, Y; Wu, H; Yang, X; Yao, W, 2018)
" In this study, we evaluated the intravitreal bioavailability and anti-inflammatory efficacy of flurbiprofen in rabbit eyes."1.46Pharmacokinetics and efficacy of intraocular flurbiprofen. ( Blazaki, S; Naoumidi, E; Tsatsakis, A; Tsatsanis, C; Tsika, C; Tsilimbaris, MK; Tzatzarakis, M, 2017)
"Caffeine is able to increase the effect of rac-Flur in the arthritic gout-type pain in rats."1.43Antinociceptive Effect of Racemic Flurbiprofen and Caffeine Co-Administration in an Arthritic Gout-Type Pain in Rats. ( Espinosa-Juárez, JV; Jaramillo-Morales, OA; Liévano-Reyes, R; López-Muñoz, FJ; Pérez-Méndez, HI; Solís-Oba, A, 2016)
" Meanwhile, the ISO-C10 contained patches increased the drug disposition in synovial fluid and enhanced the pharmacodynamic efficacy of the formulation."1.42Enhancement of skin permeation of flurbiprofen via its transdermal patches using isopulegol decanoate (ISO-C10) as an absorption enhancer: pharmacokinetic and pharmacodynamic evaluation. ( Chen, Y; Cun, D; Fang, L; Guo, W; Liu, X; Quan, P; Song, W; Wang, Z, 2015)
"R-flurbiprofen treatment increased CD4(+)CD25(+)FoxP3(+) regulatory T cells, CTLA4(+) inhibitory T cells and interleukin-10, whereas the EAE-evoked upregulation of pro-inflammatory genes in the spinal cord was strongly reduced."1.40R-flurbiprofen attenuates experimental autoimmune encephalomyelitis in mice. ( Altmann, C; Bishay, P; de Bruin, N; Ferreirós, N; Geisslinger, G; Häussler, A; Lötsch, J; Männich, J; Parnham, MJ; Schmitz, K; Tegeder, I; Ultsch, A, 2014)
"The protection against colorectal cancer (CRC) by non-steroidal anti-inflammatory drugs (NSAIDs) is in part dependent on inhibition of cyclooxygenase (COX)."1.39Comparing the effects of COX and non-COX-inhibiting NSAIDs on enhancement of apoptosis and inhibition of aberrant crypt foci formation in a rat colorectal cancer model. ( Hu, Y; LE Leu, RK; Martin, JE; Young, GP, 2013)
"R-flurbiprofen was used because it is able to reduce neuropathic pain in young mice in part by increasing anandamide."1.39Anandamide deficiency and heightened neuropathic pain in aged mice. ( Bishay, P; Ferreirós, N; Galve-Roperh, I; Häussler, A; Lim, HY; Oertel, B; Tegeder, I, 2013)
"Similarly, amyloid plaque burden, microglia activation and aberrant cell cycle events were significantly affected by CHF5074, but not DAPT, treatment."1.39Multi-target action of the novel anti-Alzheimer compound CHF5074: in vivo study of long term treatment in Tg2576 mice. ( Baldassarro, VA; Baroc, MF; Calzà, L; Fernandez, M; Ferraro, L; Giardino, L; Giuliani, A; Gusciglio, M; Imbimbo, BP; Lorenzini, L; Mangano, C; Ottonello, S; Pietrini, V; Sivilia, S; Villetti, G; Viscomi, AR, 2013)
"In patients with Duchenne muscular dystrophy (DMD) and the standard mdx mouse model of DMD, dystrophin deficiency causes loss of neuronal nitric oxide synthase (nNOSμ) from the sarcolemma, producing functional ischemia when the muscles are exercised."1.38Treatment with a nitric oxide-donating NSAID alleviates functional muscle ischemia in the mouse model of Duchenne muscular dystrophy. ( De Nardi, C; Monopoli, A; Ongini, E; Thomas, GD; Victor, RG; Ye, J, 2012)
"Sham treatment and flurbiprofen treatment did not affect Aβ pathology, and a low dose HCT 1026 (10 mg/kg; a nitric oxide-donating flurbiprofen analog that has additional useful properties, including a remarkable gastrointestinal safety) did not affect pathology either, however a higher dose of HCT 1026 (30 mg/kg) did reduce the Aβ load."1.37Transgenic AD model mice, effects of potential anti-AD treatments on inflammation, and pathology. ( Kadish, I; Miettinen, P; van Groen, T, 2011)
" In three other groups (n = 8 in each group), the selected dosage of 10 mg/kg was administrated intravenously at 6, 12 and 24 hours after I/R."1.35Therapeutic time window of flurbiprofen axetil's neuroprotective effect in a rat model of transient focal cerebral ischemia. ( Dong, HL; Liu, JL; Lu, Y; Sang, HF; Wang, C; Xiong, LZ, 2008)
"Flurbiprofen-treated rats showed severe gastrointestinal ulcerations (bleeding in 3/8 rats) and nefrotoxicity, which was not observed in nitroflurbiprofen-treated cirrhotic rats."1.34Nitroflurbiprofen, a nitric oxide-releasing cyclooxygenase inhibitor, improves cirrhotic portal hypertension in rats. ( Fevery, J; Laleman, W; Nevens, F; Van der Elst, I; Van Landeghem, L; Zeegers, M, 2007)
"We have found that chronic administration of R-flurbiprofen is able to attenuate spatial learning deficits if given prior to plaque deposition in Tg2576 mice."1.34Chronic administration of R-flurbiprofen attenuates learning impairments in transgenic amyloid precursor protein mice. ( Eriksen, JL; Golde, TE; Holloway, V; Koo, EH; Kukar, T; Murphy, MP; Nicolle, MM; Prescott, S, 2007)
" Long-term administration of flurbiprofen rescued entorhinal cortex dysfunction in transgenic mice."1.34Imaging the Abeta-related neurotoxicity of Alzheimer disease. ( Brickman, A; Brown, TR; Lee, T; Mayeux, R; Moreno, H; Small, SA; Wu, WE, 2007)
"Sham treatment, flurbiprofen, and the low-dose HCT 1026 did not affect pathology; however, a higher dose of HCT 1026 reduced both A load and amount of microglial activation surrounding plaques."1.33Transgenic AD model mice, effects of potential anti-AD treatments on inflammation and pathology. ( Kadish, I; van Groen, T, 2005)
"Main parameter was thrombus weight."1.32Interactions between aspirin and COX-2 inhibitors or NSAIDs in a rat thrombosis model. ( Bégaud, B; Boisseau, M; Moore, N; Umar, A; Upur, H; Yusup, A, 2004)
"Flurbiprofen treatment of ND rats replicated many of the biochemical and physiological abnormalities of EDN, i."1.31Dissection of metabolic, vascular, and nerve conduction interrelationships in experimental diabetic neuropathy by cyclooxygenase inhibition and acetyl-L-carnitine administration. ( Greene, DA; Larkin, D; Li, F; Marinescu, V; Pop-Busui, R; Stevens, MJ; Sullivan, K; Van Huysen, C, 2002)
" Dose-response for intestinal ulcer production was observed for rac- and (S)-flurbiprofen; animals given (R)-flurbiprofen exhibited no ulcers."1.30Mechanism of enhancement of intestinal ulcerogenicity of S-aryl propionic acids by their R-enantiomers in the rat. ( Gibson, K; Kantoci, D; Leipold, D; Liu, Y; McCracken, JD; Mineyama, Y; Murray, ED; Quiggle, D; Wechter, WJ, 1998)
"The treatment with flurbiprofen and indomethacin administered subcutaneously every 12 hours, commenced on the day of S-antigen injection and was continued until the termination of the experiment (12 days)."1.28Modulation of immune responses by cyclo-oxygenase inhibitors during intraocular inflammation. ( Bhattacherjee, P; Jaramillo, A; Paterson, CA; Sonnenfeld, G, 1992)
"Flurbiprofen treatment resulted in a significant reduction of the maximum intensity of stromal opacity in some experiments, whereas in other experiments the effect was not statistically significant."1.28The effect of flurbiprofen on herpes simplex virus type 1 stromal keratitis in mice. ( Barfknecht, CF; Epstein, RJ; Hendricks, RL; Schoenwald, RD; Sugar, J, 1990)
"In rabbit models of untreated Pseudomonas keratitis and pneumococcal keratitis, topical 1% prednisolone phosphate, 0."1.28Topical anti-inflammatory agents in an animal model of microbial keratitis. ( Gritz, DC; Kwitko, S; Lee, TY; McDonnell, PJ, 1990)
"The onset of ocular hypertension occurred within 15 min."1.28Argon laser-induced ocular hypertension: animal model of ocular inflammation. ( Gherezghiher, T; Koss, MC, 1989)
"In a study of the ocular absorption and elimination of a topically applied non-steroidal anti-inflammatory drug (NSAID), flurbiprofen, the compound was well absorbed into rabbit ocular tissues and was highly concentrated in the rabbit cornea."1.26Disposition of topical flurbiprofen in normal and aphakic rabbit eyes. ( Anderson, JA; Chen, CC; Shackleton, M; Vita, JB, 1982)

Research

Studies (75)

TimeframeStudies, this research(%)All Research%
pre-19906 (8.00)18.7374
1990's14 (18.67)18.2507
2000's23 (30.67)29.6817
2010's27 (36.00)24.3611
2020's5 (6.67)2.80

Authors

AuthorsStudies
Abrams, RPM1
Yasgar, A1
Teramoto, T1
Lee, MH1
Dorjsuren, D1
Eastman, RT1
Malik, N1
Zakharov, AV1
Li, W1
Bachani, M1
Brimacombe, K1
Steiner, JP1
Hall, MD1
Balasubramanian, A1
Jadhav, A1
Padmanabhan, R1
Simeonov, A1
Nath, A1
Yang, B1
Nie, Y1
Wang, L1
Xiong, W1
Dong, J1
Zhu, XM1
Wu, FY1
Yang, BQ1
Feng, H1
Dong, YF1
Gu, W1
Chen, J1
Okamoto, K1
Saito, Y1
Narumi, K1
Furugen, A1
Iseki, K1
Kobayashi, M1
Farhat, F1
Nofal, S1
Raafat, EM1
Eissa Ahmed, AA1
Blazaki, S1
Tsika, C1
Tzatzarakis, M1
Naoumidi, E1
Tsatsakis, A1
Tsatsanis, C1
Tsilimbaris, MK1
Lin, HJ1
Hsu, CC1
Chio, CC1
Tian, YF1
Lin, MT1
Lin, TW1
Chang, CH1
Chang, CP1
Wu, H1
Tang, C1
Tai, LW1
Yao, W1
Guo, P1
Hong, J1
Yang, X1
Li, X1
Jin, Z1
Ke, J1
Wang, Y1
Fukumoto, A1
Tajima, K1
Hori, M2
Toda, Y2
Kaku, S2
Matsumoto, H2
Alboni, S1
Benatti, C1
Capone, G1
Tascedda, F1
Brunello, N1
Sivilia, S3
Lorenzini, L3
Giuliani, A4
Gusciglio, M2
Fernandez, M1
Baldassarro, VA2
Mangano, C2
Ferraro, L3
Pietrini, V3
Baroc, MF2
Viscomi, AR1
Ottonello, S1
Villetti, G3
Imbimbo, BP7
Calzà, L5
Giardino, L4
Bishay, P3
Häussler, A3
Lim, HY1
Oertel, B1
Galve-Roperh, I1
Ferreirós, N2
Tegeder, I4
Martin, JE2
Young, GP2
LE Leu, RK2
Hu, Y2
Aytan, N2
Choi, JK2
Carreras, I2
Kowall, NW2
Jenkins, BG2
Dedeoglu, A2
McKee, AC1
Beggiato, S2
Antonelli, T2
Pidoplichko, VI1
Aroniadou-Anderjaska, V1
Prager, EM1
Figueiredo, TH1
Almeida-Suhett, CP1
Miller, SL1
Braga, MF1
Schmitz, K1
de Bruin, N1
Männich, J1
Altmann, C1
Lötsch, J1
Ultsch, A1
Parnham, MJ1
Geisslinger, G3
Porrini, V1
Lanzillotta, A2
Branca, C2
Benarese, M2
Parrella, E1
Flaibani, R1
Spano, PF1
Pizzi, M2
Chen, Y1
Quan, P1
Liu, X1
Guo, W1
Song, W1
Cun, D1
Wang, Z1
Fang, L1
Ulu, N1
Iskit, AB1
Sökmensüer, C1
Güç, MO1
Sugimoto, M1
Mitani, A1
Ichihara, T1
Sekine, S1
Hirose, T1
Endo, H1
Futaki, N1
Otsuka, N1
Liévano-Reyes, R1
Pérez-Méndez, HI1
Solís-Oba, A1
Jaramillo-Morales, OA1
Espinosa-Juárez, JV1
López-Muñoz, FJ3
Wang, C1
Liu, JL1
Sang, HF1
Lu, Y1
Dong, HL1
Xiong, LZ1
Abdul-Hay, SO1
Luo, J1
Ashghodom, RT1
Thatcher, GR1
Del Giudice, E2
D'Arrigo, A2
Leon, A2
Schmidt, H1
Marian, C1
Wijnvoord, N1
Ziebell, S1
Metzner, J1
Koch, M1
Myrczek, T1
Bechmann, I1
Kuner, R1
Costigan, M1
Dehghani, F1
L'Episcopo, F1
Tirolo, C1
Caniglia, S1
Testa, N1
Serra, PA1
Impagnatiello, F1
Morale, MC1
Marchetti, B1
Sarnico, I1
Baiguera, C1
Hutter-Paier, B1
Windisch, M1
Spano, P1
van Groen, T2
Miettinen, P1
Kadish, I2
Smith, KD1
Paylor, R1
Pautler, RG1
Thomas, GD1
Ye, J1
De Nardi, C1
Monopoli, A1
Ongini, E2
Victor, RG1
Pop-Busui, R1
Marinescu, V1
Van Huysen, C1
Li, F1
Sullivan, K1
Greene, DA1
Larkin, D1
Stevens, MJ1
Rosi, S1
McGann, K1
Hauss-Wegrzyniak, B1
Wenk, GL2
Wilcock, DM1
Munireddy, SK1
Rosenthal, A1
Ugen, KE1
Gordon, MN2
Morgan, D3
Umar, A1
Boisseau, M1
Yusup, A1
Upur, H1
Bégaud, B1
Moore, N1
Gasparini, L1
Wilcock, D1
Townsend, KP1
Praticò, D1
Stock, N1
Munoz, B1
Wrigley, JD1
Shearman, MS1
Beher, D1
Peachey, J1
Williamson, TL1
Bain, G1
Chen, W1
Jiang, X1
St-Jacques, R1
Prasit, P1
Peyman, GA2
Kazi, AA2
Riazi-Esfahani, M2
Aydin, E2
Kivilcim, M2
Sanders, DR2
Takeuchi, K1
Yokota, A1
Tanaka, A1
Takahira, Y1
Anuar, F1
Whiteman, M1
Bhatia, M1
Moore, PK1
Laleman, W1
Van Landeghem, L1
Van der Elst, I1
Zeegers, M1
Fevery, J1
Nevens, F1
Kukar, T1
Prescott, S1
Eriksen, JL1
Holloway, V1
Murphy, MP1
Koo, EH1
Golde, TE1
Nicolle, MM1
Colavito, D1
Dalle Carbonare, M1
Facchinetti, F1
Volta, R1
Serneels, L1
De Strooper, B1
Moreno, H1
Wu, WE1
Lee, T1
Brickman, A1
Mayeux, R1
Brown, TR1
Small, SA1
Anderson, JA1
Chen, CC1
Vita, JB1
Shackleton, M1
Kizior, MJ1
Chai, JY1
Turner, DW1
Stern, PH1
Zernicke, RF1
Wohl, GR1
Greenwald, RA1
Moak, SA1
Leng, W1
Golub, LM1
Wechter, WJ2
McCracken, JD2
Kantoci, D1
Murray, ED2
Quiggle, D2
Leipold, D1
Gibson, K1
Mineyama, Y1
Liu, Y1
Ventura, R2
Díaz, I1
Fernández-Guasti, A1
Tost, D1
Cabré, F2
Mauleón, D2
Gorman, PJ1
Saggers, G1
Ehrlich, P1
Mackay, DR1
Graham, WP1
Sugibayashi, K1
Yanagimoto, G1
Hayashi, T1
Seki, T1
Juni, K1
Morimoto, Y1
Leipold, DD1
Barrios, RS1
Greenberg, NM1
Niederberger, E1
Israr, E1
Gühring, H1
Brune, K1
Euchenhofer, C1
Grösch, S1
Buritova, J1
Besson, JM1
Díaz, MI1
Hernández, GP1
Domínguez, AM1
García, ML1
Jantzen, PT1
Connor, KE1
DiCarlo, G1
Wallace, JL1
Rojiani, AM1
Coppola, D1
Woodland, J1
Currey, HL1
Vernon-Roberts, B1
Jaramillo, A1
Bhattacherjee, P1
Sonnenfeld, G1
Paterson, CA1
McCaig, DJ1
Aitken, S1
De Jonckheere, B1
Ohadi, C1
Litwin, KL1
Moreira, H2
Kwitko, S2
Gauderman, WJ1
Gritz, DC2
Gwon, A1
Jones, R1
McDonnell, PJ3
Massart-Leën, AM1
Burvenich, C1
Vandeputte-Van Messom, G1
Hilderson, H1
Fasano, AP1
Silverman, DL1
Coates, TD1
Sevanian, A1
Hendricks, RL1
Barfknecht, CF1
Schoenwald, RD1
Epstein, RJ1
Sugar, J1
Lee, TY1
Tilden, ME1
Boney, RS1
Goldenberg, MM1
Rosenbaum, JT1
Wang, RF1
Camras, CB1
Podos, SM1
Lee, KW1
Bhuyan, KC1
Bhuyan, DK1
Robin, JB1
Regis-Pacheco, LF1
Kash, RL1
Schanzlin, DJ1
Gherezghiher, T1
Koss, MC1
Wood, JJ1
Grbic, JT1
Rodrick, ML1
Jordan, A1
Mannick, JA1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Placebo-Controlled, Ascending Single-Dose Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of CHF 5074 in Healthy Young Male Subjects[NCT00954252]Phase 184 participants (Actual)Interventional2009-10-31Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Reviews

2 reviews available for flurbiprofen and Disease Models, Animal

ArticleYear
Activity of flurbiprofen and chemically related anti-inflammatory drugs in models of Alzheimer's disease.
    Brain research. Brain research reviews, 2005, Volume: 48, Issue:2

    Topics: Alzheimer Disease; Animals; Anti-Inflammatory Agents, Non-Steroidal; Disease Models, Animal; Flurbip

2005
Novel therapeutic opportunities for Alzheimer's disease: focus on nonsteroidal anti-inflammatory drugs.
    FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2005, Volume: 19, Issue:12

    Topics: Aged; Aged, 80 and over; Alzheimer Disease; Animals; Animals, Genetically Modified; Anti-Inflammator

2005

Other Studies

73 other studies available for flurbiprofen and Disease Models, Animal

ArticleYear
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
    Proceedings of the National Academy of Sciences of the United States of America, 2020, 12-08, Volume: 117, Issue:49

    Topics: Animals; Antiviral Agents; Artificial Intelligence; Chlorocebus aethiops; Disease Models, Animal; Dr

2020
Flurbiprofen axetil protects against cerebral ischemia/reperfusion injury via regulating miR-30c-5p and SOX9.
    Chemical biology & drug design, 2022, Volume: 99, Issue:2

    Topics: Animals; Brain; Brain Ischemia; Cytokines; Disease Models, Animal; Flurbiprofen; Male; Malondialdehy

2022
Development of galangal essential oil-based microemulsion gel for transdermal delivery of flurbiprofen: simultaneous permeability evaluation of flurbiprofen and 1,8-cineole.
    Drug development and industrial pharmacy, 2020, Volume: 46, Issue:1

    Topics: Administration, Cutaneous; Alpinia; Animals; Anti-Inflammatory Agents, Non-Steroidal; Area Under Cur

2020
Comparison of the nephroprotective effects of non-steroidal anti-inflammatory drugs on cisplatin-induced nephrotoxicity in vitro and in vivo.
    European journal of pharmacology, 2020, Oct-05, Volume: 884

    Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Autophagy; Celecoxib; Cell Line; Cisplatin; Cytopr

2020
Akt / GSK3β / Nrf2 / HO-1 pathway activation by flurbiprofen protects the hippocampal neurons in a rat model of glutamate excitotoxicity.
    Neuropharmacology, 2021, 09-15, Volume: 196

    Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antioxidants; Anxiety; Apoptosis; Behavior, Animal

2021
Pharmacokinetics and efficacy of intraocular flurbiprofen.
    Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie, 2017, Volume: 255, Issue:12

    Topics: Animals; Cyclooxygenase Inhibitors; Disease Models, Animal; Dose-Response Relationship, Drug; Endoph

2017
Gamma-Secretase Inhibitors Attenuate Neurotrauma and Neurogenic Acute Lung Injury in Rats by Rescuing the Accumulation of Hypertrophic Microglia.
    Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology, 2017, Volume: 44, Issue:5

    Topics: Acute Lung Injury; Alanine; Amyloid Precursor Protein Secretases; Animals; Azepines; Blood-Brain Bar

2017
Flurbiprofen axetil attenuates cerebral ischemia/reperfusion injury by reducing inflammation in a rat model of transient global cerebral ischemia/reperfusion.
    Bioscience reports, 2018, 08-31, Volume: 38, Issue:4

    Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Brain Ischemia; Disease Models, Animal; Flurbiprof

2018
Analgesic effect of S (+)-flurbiprofen plaster in a rat model of knee arthritis: analysis of gait and synovial fluid prostaglandin E
    The Journal of pharmacy and pharmacology, 2018, Volume: 70, Issue:7

    Topics: Analgesics; Animals; Arthritis, Experimental; Dinoprostone; Disease Models, Animal; Dose-Response Re

2018
Neither all anti-inflammatory drugs nor all doses are effective in accelerating the antidepressant-like effect of fluoxetine in an animal model of depression.
    Journal of affective disorders, 2018, 08-01, Volume: 235

    Topics: Animals; Anti-Inflammatory Agents; Antidepressive Agents; Behavior, Animal; Celecoxib; Depression; D

2018
Multi-target action of the novel anti-Alzheimer compound CHF5074: in vivo study of long term treatment in Tg2576 mice.
    BMC neuroscience, 2013, Apr-05, Volume: 14

    Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Analysis of Variance; Anim

2013
Anandamide deficiency and heightened neuropathic pain in aged mice.
    Neuropharmacology, 2013, Volume: 71

    Topics: Aging; Amidohydrolases; Animals; Arachidonic Acids; Behavior, Animal; Brain; Cyclooxygenase 1; Cyclo

2013
Comparing the effects of COX and non-COX-inhibiting NSAIDs on enhancement of apoptosis and inhibition of aberrant crypt foci formation in a rat colorectal cancer model.
    Anticancer research, 2013, Volume: 33, Issue:9

    Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Apoptosis; Azoxymethane; Colorectal Neoplasms; Cyc

2013
Combination therapy in a transgenic model of Alzheimer's disease.
    Experimental neurology, 2013, Volume: 250

    Topics: Alzheimer Disease; Animals; Behavior, Animal; Brain; Cognition; Disease Models, Animal; Drug Therapy

2013
R-flurbiprofen improves tau, but not Aß pathology in a triple transgenic model of Alzheimer's disease.
    Brain research, 2013, Dec-06, Volume: 1541

    Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Anti-Inflammatory Agents, Non-Steroidal; Disease

2013
CHF5074 and LY450139 sub-acute treatments differently affect cortical extracellular glutamate levels in pre-plaque Tg2576 mice.
    Neuroscience, 2014, Apr-25, Volume: 266

    Topics: Alanine; Alzheimer Disease; Animals; Azepines; Cyclopropanes; Disease Models, Animal; Extracellular

2014
ASIC1a activation enhances inhibition in the basolateral amygdala and reduces anxiety.
    The Journal of neuroscience : the official journal of the Society for Neuroscience, 2014, Feb-26, Volume: 34, Issue:9

    Topics: Acid Sensing Ion Channels; Action Potentials; Ammonium Compounds; Amygdala; Animals; Anti-Inflammato

2014
R-flurbiprofen attenuates experimental autoimmune encephalomyelitis in mice.
    EMBO molecular medicine, 2014, Volume: 6, Issue:11

    Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Brain; Disease Models, Animal; Encephalomyelitis,

2014
CHF5074 (CSP-1103) induces microglia alternative activation in plaque-free Tg2576 mice and primary glial cultures exposed to beta-amyloid.
    Neuroscience, 2015, Aug-27, Volume: 302

    Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Animals; Animals, Newborn;

2015
Enhancement of skin permeation of flurbiprofen via its transdermal patches using isopulegol decanoate (ISO-C10) as an absorption enhancer: pharmacokinetic and pharmacodynamic evaluation.
    The Journal of pharmacy and pharmacology, 2015, Volume: 67, Issue:9

    Topics: Administration, Cutaneous; Animals; Anti-Inflammatory Agents, Non-Steroidal; Chemistry, Pharmaceutic

2015
The effects of aspirin, flurbiprofen, and NO-donating acetylsalicylic acid (NCX 4016) on mice models of endotoxic and septic shock.
    Turkish journal of medical sciences, 2015, Volume: 45, Issue:4

    Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Disease Models, Animal; Flurbiprofen; Liv

2015
Analgesic Effect of the Newly Developed S(+)-Flurbiprofen Plaster on Inflammatory Pain in a Rat Adjuvant-Induced Arthritis Model.
    Drug development research, 2016, Volume: 77, Issue:1

    Topics: Administration, Topical; Analgesics; Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Ex

2016
Antinociceptive Effect of Racemic Flurbiprofen and Caffeine Co-Administration in an Arthritic Gout-Type Pain in Rats.
    Drug development research, 2016, Volume: 77, Issue:4

    Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Gouty; Caffeine; Disease Models, Animal

2016
Therapeutic time window of flurbiprofen axetil's neuroprotective effect in a rat model of transient focal cerebral ischemia.
    Chinese medical journal, 2008, Dec-20, Volume: 121, Issue:24

    Topics: Animals; Cyclooxygenase Inhibitors; Disease Models, Animal; Flurbiprofen; Infusions, Intravenous; Is

2008
NO-flurbiprofen reduces amyloid-beta, is neuroprotective in cell culture, and enhances cognition in response to cholinergic blockade.
    Journal of neurochemistry, 2009, Volume: 111, Issue:3

    Topics: Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Animals; Avoidance Learning; Cell Line, Tumor

2009
CHF5074, a novel gamma-secretase modulator, restores hippocampal neurogenesis potential and reverses contextual memory deficit in a transgenic mouse model of Alzheimer's disease.
    Journal of Alzheimer's disease : JAD, 2010, Volume: 20, Issue:1

    Topics: Age Factors; Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Analysis of V

2010
R-flurbiprofen suppresses distal nonmucin-producing colorectal tumors in azoxymethane-treated rats, without suppressing eicosanoid production.
    American journal of physiology. Gastrointestinal and liver physiology, 2010, Volume: 298, Issue:6

    Topics: Animals; Antineoplastic Agents; Azoxymethane; Carcinogens; Colorectal Neoplasms; Dinoprostone; Disea

2010
R-flurbiprofen reduces neuropathic pain in rodents by restoring endogenous cannabinoids.
    PloS one, 2010, May-13, Volume: 5, Issue:5

    Topics: Amidohydrolases; Analgesics; Animals; Biomarkers; Cannabinoids; Disease Models, Animal; Fluorescent

2010
Combining nitric oxide release with anti-inflammatory activity preserves nigrostriatal dopaminergic innervation and prevents motor impairment in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease.
    Journal of neuroinflammation, 2010, Nov-23, Volume: 7

    Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Anti-Inflammatory Agents, Non-Steroidal; Corp

2010
The γ-secretase modulator CHF5074 reduces the accumulation of native hyperphosphorylated tau in a transgenic mouse model of Alzheimer's disease.
    Journal of molecular neuroscience : MN, 2011, Volume: 45, Issue:1

    Topics: Amyloid beta-Peptides; Amyloid Precursor Protein Secretases; Animals; Cells, Cultured; Cyclooxygenas

2011
Transgenic AD model mice, effects of potential anti-AD treatments on inflammation, and pathology.
    Journal of Alzheimer's disease : JAD, 2011, Volume: 24, Issue:2

    Topics: Alzheimer Disease; Amyloid; Amyloid beta-Protein Precursor; Analysis of Variance; Animals; Anti-Infl

2011
R-flurbiprofen improves axonal transport in the Tg2576 mouse model of Alzheimer's disease as determined by MEMRI.
    Magnetic resonance in medicine, 2011, Volume: 65, Issue:5

    Topics: Alzheimer Disease; Animals; Anti-Inflammatory Agents, Non-Steroidal; Axonal Transport; Disease Model

2011
Treatment with a nitric oxide-donating NSAID alleviates functional muscle ischemia in the mouse model of Duchenne muscular dystrophy.
    PloS one, 2012, Volume: 7, Issue:11

    Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Biomechanical Phenomena; Disease Models, Animal; F

2012
CHF5074 restores visual memory ability and pre-synaptic cortical acetylcholine release in pre-plaque Tg2576 mice.
    Journal of neurochemistry, 2013, Volume: 124, Issue:5

    Topics: Acetylcholine; Alzheimer Disease; Animals; Cerebral Cortex; Cyclopropanes; Disease Models, Animal; F

2013
Dissection of metabolic, vascular, and nerve conduction interrelationships in experimental diabetic neuropathy by cyclooxygenase inhibition and acetyl-L-carnitine administration.
    Diabetes, 2002, Volume: 51, Issue:8

    Topics: Acetylcarnitine; Animals; Anti-Inflammatory Agents, Non-Steroidal; Cyclooxygenase 2; Cyclooxygenase

2002
The influence of brain inflammation upon neuronal adenosine A2B receptors.
    Journal of neurochemistry, 2003, Volume: 86, Issue:1

    Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Chronic Disease; Disease Models, Animal; Encephali

2003
Microglial activation facilitates Abeta plaque removal following intracranial anti-Abeta antibody administration.
    Neurobiology of disease, 2004, Volume: 15, Issue:1

    Topics: Alzheimer Disease; Amyloid beta-Peptides; Animals; Anti-Inflammatory Agents; Antibodies; Brain; Dexa

2004
Interactions between aspirin and COX-2 inhibitors or NSAIDs in a rat thrombosis model.
    Fundamental & clinical pharmacology, 2004, Volume: 18, Issue:5

    Topics: Administration, Oral; Animals; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Celecoxib; Cyclooxy

2004
Transgenic AD model mice, effects of potential anti-AD treatments on inflammation and pathology.
    Brain research. Brain research reviews, 2005, Volume: 48, Issue:2

    Topics: Acetylcholinesterase; Age Factors; Alzheimer Disease; Amyloid beta-Protein Precursor; Animals; Anti-

2005
The geminal dimethyl analogue of Flurbiprofen as a novel Abeta42 inhibitor and potential Alzheimer's disease modifying agent.
    Bioorganic & medicinal chemistry letters, 2006, Apr-15, Volume: 16, Issue:8

    Topics: Administration, Oral; Alzheimer Disease; Amyloid beta-Peptides; Animals; Anti-Inflammatory Agents, N

2006
The effect of combinations of flurbiprofen, low molecular weight heparin, and doxycycline on the inhibition of corneal neovascularization.
    Cornea, 2006, Volume: 25, Issue:5

    Topics: Administration, Topical; Animals; Cornea; Corneal Neovascularization; Disease Models, Animal; Doxycy

2006
Factors involved in upregulation of inducible nitric oxide synthase in rat small intestine following administration of nonsteroidal anti-inflammatory drugs.
    Digestive diseases and sciences, 2006, Volume: 51, Issue:7

    Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Cyclooxygenase Inhibitors; Diclofenac; Dinoproston

2006
Prevention of corneal neovascularization: evaluation of various commercially available compounds in an experimental rat model.
    Cornea, 2006, Volume: 25, Issue:7

    Topics: Animals; Anti-Bacterial Agents; Cornea; Corneal Neovascularization; Cyclooxygenase Inhibitors; Disea

2006
Flurbiprofen and its nitric oxide-releasing derivative protect against septic shock in rats.
    Inflammation research : official journal of the European Histamine Research Society ... [et al.], 2006, Volume: 55, Issue:11

    Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Blood Pressure; Cecum; Disease Models, Animal; Flu

2006
Nitroflurbiprofen, a nitric oxide-releasing cyclooxygenase inhibitor, improves cirrhotic portal hypertension in rats.
    Gastroenterology, 2007, Volume: 132, Issue:2

    Topics: Animals; Cyclooxygenase Inhibitors; Disease Models, Animal; Dose-Response Relationship, Drug; Endoth

2007
Chronic administration of R-flurbiprofen attenuates learning impairments in transgenic amyloid precursor protein mice.
    BMC neuroscience, 2007, Jul-24, Volume: 8

    Topics: Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Animals; Brain; Cyclooxyge

2007
1-(3',4'-Dichloro-2-fluoro[1,1'-biphenyl]-4-yl)-cyclopropanecarboxylic acid (CHF5074), a novel gamma-secretase modulator, reduces brain beta-amyloid pathology in a transgenic mouse model of Alzheimer's disease without causing peripheral toxicity.
    The Journal of pharmacology and experimental therapeutics, 2007, Volume: 323, Issue:3

    Topics: Aging; Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Amyloid Precursor P

2007
Imaging the Abeta-related neurotoxicity of Alzheimer disease.
    Archives of neurology, 2007, Volume: 64, Issue:10

    Topics: Aged, 80 and over; Algorithms; Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precur

2007
Disposition of topical flurbiprofen in normal and aphakic rabbit eyes.
    Archives of ophthalmology (Chicago, Ill. : 1960), 1982, Volume: 100, Issue:4

    Topics: Absorption; Animals; Aphakia, Postcataract; Cataract Extraction; Choroid; Cornea; Disease Models, An

1982
Flurbiprofen effects on bone resorption.
    Northwestern dental research, 1993,Spring, Volume: 4, Issue:1

    Topics: Analysis of Variance; Animals; Bone and Bones; Bone Resorption; Disease Models, Animal; Fetus; Flurb

1993
Administration of systemic matrix metalloproteinase inhibitors maintains bone mechanical integrity in adjuvant arthritis.
    The Journal of rheumatology, 1997, Volume: 24, Issue:7

    Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Experimental; Body Weight; Cross-Linkin

1997
Mechanism of enhancement of intestinal ulcerogenicity of S-aryl propionic acids by their R-enantiomers in the rat.
    Digestive diseases and sciences, 1998, Volume: 43, Issue:6

    Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Disease Models, Animal; Dose-Response Relationship

1998
Antinociceptive effects of S(+)-ketoprofen and other analgesic drugs in a rat model of pain induced by uric acid.
    Journal of clinical pharmacology, 1998, Volume: 38, Issue:S1

    Topics: Administration, Oral; Analgesics, Non-Narcotic; Analgesics, Opioid; Animals; Biotransformation; Dise

1998
Effects of topical nitroglycerin and flurbiprofen in the rat comb burn model.
    Annals of plastic surgery, 1999, Volume: 42, Issue:5

    Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Burns; Disease Models, Animal; Evaluation Studies

1999
Analysis of skin disposition of flurbiprofen after topical application in hairless rats.
    Journal of controlled release : official journal of the Controlled Release Society, 1999, Nov-01, Volume: 62, Issue:1-2

    Topics: Administration, Cutaneous; Animals; Bradykinin; Disease Models, Animal; Drug Implants; Epinephrine;

1999
E-7869 (R-flurbiprofen) inhibits progression of prostate cancer in the TRAMP mouse.
    Cancer research, 2000, Apr-15, Volume: 60, Issue:8

    Topics: Adenocarcinoma; Animals; Body Weight; Dietary Fats; Disease Models, Animal; Disease Progression; Flu

2000
Inhibition of NF-kappaB and AP-1 activation by R- and S-flurbiprofen.
    FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2001, Volume: 15, Issue:1

    Topics: Active Transport, Cell Nucleus; Animals; Cell Line; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; C

2001
Urethane anaesthesia could partly mask antinociceptive effects of non-steroidal anti-inflammatory drugs: a spinal c-Fos protein study.
    Brain research, 2001, Feb-09, Volume: 891, Issue:1-2

    Topics: Anesthetics, Intravenous; Animals; Anti-Inflammatory Agents, Non-Steroidal; Carrageenan; Cell Count;

2001
Analysis of antinociceptive effects of flurbiprofen enantiomers in a rat model of arthritic pain.
    Methods and findings in experimental and clinical pharmacology, 2000, Volume: 22, Issue:8

    Topics: Analgesics; Animals; Area Under Curve; Arthritis; Disease Models, Animal; Dose-Response Relationship

2000
Microglial activation and beta -amyloid deposit reduction caused by a nitric oxide-releasing nonsteroidal anti-inflammatory drug in amyloid precursor protein plus presenilin-1 transgenic mice.
    The Journal of neuroscience : the official journal of the Society for Neuroscience, 2002, Mar-15, Volume: 22, Issue:6

    Topics: Administration, Oral; Alzheimer Disease; Amyloid beta-Peptides; Amyloid beta-Protein Precursor; Anim

2002
The effect of anti-inflammatory and antirheumatic drugs on inflammation in the rat.
    Current medical research and opinion, 1977, Volume: 5, Issue:1

    Topics: Acute Disease; Animals; Anti-Inflammatory Agents; Chronic Disease; Disease Models, Animal; Exudates

1977
Modulation of immune responses by cyclo-oxygenase inhibitors during intraocular inflammation.
    Current eye research, 1992, Volume: 11, Issue:6

    Topics: Animals; Antigens; Arrestin; Autoantibodies; Dinoprostone; Disease Models, Animal; Eye Proteins; Fem

1992
Comparison of the effects of cromakalim in trachea isolated from normal and albumin-sensitive guinea-pigs.
    The Journal of pharmacy and pharmacology, 1992, Volume: 44, Issue:10

    Topics: Acetylcholine; Albumins; Animals; Asthma; Benzopyrans; Bronchodilator Agents; Cromakalim; Disease Mo

1992
Anti-inflammatory therapy and outcome in a guinea pig model of Pseudomonas keratitis.
    Cornea, 1992, Volume: 11, Issue:5

    Topics: Analysis of Variance; Animals; Anti-Inflammatory Agents, Non-Steroidal; Dicarboxylic Acids; Disease

1992
Partial prostaglandin-mediated mechanism controlling the release of cortisol in plasma after intravenous administration of endotoxins.
    Domestic animal endocrinology, 1992, Volume: 9, Issue:4

    Topics: Animals; Disease Models, Animal; Female; Fever; Flurbiprofen; Goat Diseases; Goats; Hydrocortisone;

1992
Treatment of experimental Pseudomonas keratitis with cyclo-oxygenase and lipoxygenase inhibitors.
    Ophthalmology, 1991, Volume: 98, Issue:11

    Topics: Administration, Topical; Animals; Corneal Ulcer; Dinoprostone; Disease Models, Animal; Eye Infection

1991
The effect of flurbiprofen on herpes simplex virus type 1 stromal keratitis in mice.
    Investigative ophthalmology & visual science, 1990, Volume: 31, Issue:8

    Topics: Animals; Dexamethasone; Disease Models, Animal; Female; Flurbiprofen; Keratitis, Dendritic; Mice; Mi

1990
Topical anti-inflammatory agents in an animal model of microbial keratitis.
    Archives of ophthalmology (Chicago, Ill. : 1960), 1990, Volume: 108, Issue:7

    Topics: Administration, Topical; Animals; Anti-Inflammatory Agents; Disease Models, Animal; Flurbiprofen; Ke

1990
The effects of topical S(+)-ibuprofen on interleukin-1 induced ocular inflammation in a rabbit model.
    Journal of ocular pharmacology, 1990,Summer, Volume: 6, Issue:2

    Topics: Administration, Topical; Animals; Aqueous Humor; Capillary Permeability; Cell Count; Disease Models,

1990
The role of prostaglandins in the para-aminoclonidine-induced reduction of intraocular pressure.
    Transactions of the American Ophthalmological Society, 1989, Volume: 87

    Topics: Administration, Topical; Animals; Aqueous Humor; Clonidine; Dinoprost; Dinoprostone; Disease Models,

1989
The histopathology of corneal neovascularization. Inhibitor effects.
    Archives of ophthalmology (Chicago, Ill. : 1960), 1985, Volume: 103, Issue:2

    Topics: Animals; Chemotaxis, Leukocyte; Cornea; Corneal Injuries; Disease Models, Animal; Electrocoagulation

1985
Argon laser-induced ocular hypertension: animal model of ocular inflammation.
    Journal of ocular pharmacology, 1989,Spring, Volume: 5, Issue:1

    Topics: Animals; Aqueous Humor; Argon; Disease Models, Animal; Endophthalmitis; Female; Flurbiprofen; Gangli

1989
Suppression of interleukin 2 production in an animal model of thermal injury is related to prostaglandin synthesis.
    Archives of surgery (Chicago, Ill. : 1960), 1987, Volume: 122, Issue:2

    Topics: Animals; Burns; Disease Models, Animal; Flurbiprofen; Indomethacin; Interleukin-2; Lymphocyte Activa

1987